000125754 001__ 125754
000125754 005__ 20241125101130.0
000125754 0247_ $$2doi$$a10.3390/ijms24086892
000125754 0248_ $$2sideral$$a133364
000125754 037__ $$aART-2023-133364
000125754 041__ $$aeng
000125754 100__ $$aGenova, R.
000125754 245__ $$aCollateral sensitivity to fosfomycin of tobramycin-resistant mutants of Pseudomonas aeruginosa is contingent on bacterial genomic background
000125754 260__ $$c2023
000125754 5060_ $$aAccess copy available to the general public$$fUnrestricted
000125754 5203_ $$aUnderstanding the consequences in bacterial physiology of the acquisition of drug resistance is needed to identify and exploit the weaknesses derived from it. One of them is collateral sensitivity, a potentially exploitable phenotype that, unfortunately, is not always conserved among different isolates. The identification of robust, conserved collateral sensitivity patterns is then relevant for the translation of this knowledge into clinical practice. We have previously identified a robust fosfomycin collateral sensitivity pattern of Pseudomonas aeruginosa that emerged in different tobramycin-resistant clones. To go one step further, here, we studied if the acquisition of resistance to tobramycin is associated with robust collateral sensitivity to fosfomycin among P. aeruginosa isolates. To that aim, we analyzed, using adaptive laboratory evolution approaches, 23 different clinical isolates of P. aeruginosa presenting diverse mutational resistomes. Nine of them showed collateral sensitivity to fosfomycin, indicating that this phenotype is contingent on the genetic background. Interestingly, collateral sensitivity to fosfomycin was linked to a larger increase in tobramycin minimal inhibitory concentration. Further, we unveiled that fosA low expression, rendering a higher intracellular accumulation of fosfomycin, and a reduction in the expression of the P. aeruginosa alternative peptidoglycan-recycling pathway enzymes, might be on the basis of the collateral sensitivity phenotype.
000125754 536__ $$9info:eu-repo/grantAgreement/ES/MICINN-AEI/PID2020-113521RB-I00
000125754 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000125754 590__ $$a4.9$$b2023
000125754 592__ $$a1.179$$b2023
000125754 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b66 / 313 = 0.211$$c2023$$dQ1$$eT1
000125754 593__ $$aMedicine (miscellaneous)$$c2023$$dQ1
000125754 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b68 / 231 = 0.294$$c2023$$dQ2$$eT1
000125754 593__ $$aPhysical and Theoretical Chemistry$$c2023$$dQ1
000125754 593__ $$aComputer Science Applications$$c2023$$dQ1
000125754 593__ $$aInorganic Chemistry$$c2023$$dQ1
000125754 593__ $$aSpectroscopy$$c2023$$dQ1
000125754 593__ $$aOrganic Chemistry$$c2023$$dQ1
000125754 593__ $$aMolecular Biology$$c2023$$dQ2
000125754 593__ $$aCatalysis$$c2023$$dQ2
000125754 594__ $$a8.1$$b2023
000125754 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000125754 700__ $$aLaborda, P.
000125754 700__ $$aCuesta, T.
000125754 700__ $$aMartínez, J. L.
000125754 700__ $$aSanz-García, F.$$uUniversidad de Zaragoza
000125754 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000125754 773__ $$g24, 8 (2023), 6892 [15 pp.]$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000125754 8564_ $$s1872187$$uhttps://zaguan.unizar.es/record/125754/files/texto_completo.pdf$$yVersión publicada
000125754 8564_ $$s2768620$$uhttps://zaguan.unizar.es/record/125754/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000125754 909CO $$ooai:zaguan.unizar.es:125754$$particulos$$pdriver
000125754 951__ $$a2024-11-22-11:58:46
000125754 980__ $$aARTICLE